Company description

HTL is a biotechnology company, leading the way in the design, development and production of pharmaceutical grade hyaluronic acid (hyaluronan) and other functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients.

With 25 years of proven experience, HTL is recognized for producing Hyaluronic Acid that features the highest quality standards for premium medical applications and meets every market need over the long term. Our approach to growth is to innovate in partnership with our clients and create value for the medical products of both today and tomorrow.  

HTL is developing new Glycosaminoglycans, i.e. Heparosan and Chondroitin, as well as functionalized Glycosaminoglycan derivatives (based on Hyaluronan, Heparosan or Chondroitin). HTL improves the functionalities of the end-products by controlling the physico-chemical characteristics, biological properties and durability of these biopolymers.

HTL conducts its production activities in fully compliant cGMP facilities. HTL organization is built on the principle of consistently understanding and meeting the specific needs of its customers from early development to market success, while providing expert support at every stage from R&D to Technical, Analytical and Regulatory, supporting its customers through the entire process.


Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: API Contract Manufacturing |Biomanufacturing |Biopharmaceuticals (general category) More

Upcoming events

13 oct 2020

CPhI Worldwide 2020

13 - 15 October 2020 Milan, Italy Visit us at stand 20K80 Book a meeting See our Exhibitor Profile   See full Exhibitor List

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 42G13 See our Exhibitor Profile   See full Exhibitor List

News about HTL

HTL invests in GMP manufacturing capacity

30 Oct 2019

HTL invests in GMP manufacturing capacity

HTL, world leading supplier of Hyaluronic Acid and other biopolymer solutions, announces it is investing in a state-of-the-art production facility that will multiply its injectable grade sodium hyaluronate production capacity by 2.5 by 2021. This new capacity represents a much-needed opening in a global market under high pressure.

Read more